BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34126361)

  • 1. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
    Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
    Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylation regulates ribonucleotide reductase activity and cancer cell growth.
    Chen G; Luo Y; Warncke K; Sun Y; Yu DS; Fu H; Behera M; Ramalingam SS; Doetsch PW; Duong DM; Lammers M; Curran WJ; Deng X
    Nat Commun; 2019 Jul; 10(1):3213. PubMed ID: 31324785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
    Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y
    Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2).
    Chen CW; Li Y; Hu S; Zhou W; Meng Y; Li Z; Zhang Y; Sun J; Bo Z; DePamphilis ML; Yen Y; Han Z; Zhu W
    Oncogene; 2019 Mar; 38(13):2364-2379. PubMed ID: 30518875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
    Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
    Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair.
    Fujii N; Evison BJ; Actis ML; Inoue A
    Bioorg Med Chem; 2015 Nov; 23(21):6912-21. PubMed ID: 26462050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
    Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
    Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
    Goss KL; Gordon DJ
    Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
    Foskolou IP; Jorgensen C; Leszczynska KB; Olcina MM; Tarhonskaya H; Haisma B; D'Angiolella V; Myers WK; Domene C; Flashman E; Hammond EM
    Mol Cell; 2017 Apr; 66(2):206-220.e9. PubMed ID: 28416140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
    Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
    Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
    Rieunier G; Wu X; Harris LE; Mills JV; Nandakumar A; Colling L; Seraia E; Hatch SB; Ebner DV; Folkes LK; Weyer-Czernilofsky U; Bogenrieder T; Ryan AJ; Macaulay VM
    Cancer Res; 2021 Apr; 81(8):2128-2141. PubMed ID: 33509941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
    Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
    Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
    Jordheim LP; Guittet O; Lepoivre M; Galmarini CM; Dumontet C
    Mol Cancer Ther; 2005 Aug; 4(8):1268-76. PubMed ID: 16093443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
    Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
    Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.
    Chen Z; Zhou J; Zhang Y; Bepler G
    Biochem Biophys Res Commun; 2011 Sep; 413(2):383-8. PubMed ID: 21893046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.